GEO-CM02 under development as a universal vaccine to combat the evolution of SARS-CoV-2 variants such as Omicron
ATLANTA, GA, December 1, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in the development of human vaccines and cancer immunotherapies, today announced that its Scientific Director, Mark J. Newman, Ph.D ., participated in an expert roundtable on designing approaches to produce a universal vaccine against SARS-CoV-2 at the World Congress on Vaccines and Immunotherapy, to be held from November 30 to December 2 in San Diego, California. Dr Newman also presented data from ongoing studies of GEO-CM02, GeoVax’s investigational coronavirus vaccine.
The first generation SARS-CoV-2 vaccines were rapidly developed and found to be very effective in the human population and were designed to encode the Spike (S) protein with the aim of inducing high levels of antibodies neutralizers. However, the potential limitations of focusing tightly on S become apparent with emerging variants that partially escape neutralization by vaccine-induced antibodies, as currently demonstrated with the emergence of the Omicron variant originally discovered in South Africa. but which is now spreading globally. Thus, the efficacy of these vaccines against new variants of SARS-CoV-2 and future coronavirus spillover events remains an important question.
Using its new modified Ankara virus – Virus Like Particle (GV-MVA-VLPMT), GeoVax has developed a strategy for designing vaccines believed to induce broader immunity through the inclusion of several genetically conserved structural and non-structural proteins of the target pathogen. The GV-MVA-VLPMT is known to induce a balanced humoral (antibody) and cellular (T cell) response against multiple encoded immunogens, potentially limiting immune leakage against emerging variants. Expression of SARS-CoV-2 spike, membrane and envelope proteins by MVA supports the in vivo formation of virus-like particles, or VLPs, that induce both antibody and T-cell responses. Incorporation of sequence-conserved structural and non-structural proteins can provide targets for T cell responses to increase the extent and function of immune responses induced by the vaccine. This strategy provides the basis for generating a universal vaccine with increased potential to alleviate the disease burden caused by circulating coronaviruses.
In his speech, Dr. Newman discussed GeoVax’s vaccine design strategy to develop a universal vaccine against SARS-CoV-2 and presented efficacy and immunogenicity data for the primary and first vaccine candidate. generation of the company, GEO-CM02, which encodes the Spike (S), membrane (M) and envelope (E) proteins. Dr. Newman’s presentation is available on the GeoVax website at www.geovax.com/investors/events.
Dr Newman commented, âOur studies continue to support the use of MVA as a vector for the design and production of next-generation vaccines encoding several coronavirus proteins. The lead candidate encodes S protein as an antibody target and M and E proteins as T cell targets. The combination of S, M and E protein expression supports in vivo Optimal VLP formation and immunogenicity. In our small animal studies, we measured functional immune responses after a single dose that mediated protection against infection and pathogenesis, including protection against the more virulent beta variant.
About GV-MVA-VLPMT Platform
GeoVax GV-MVA-VLPMT The vaccine platform uses Modified Vaccinia Ankara (MVA), a large virus capable of carrying multiple vaccine antigens, which expresses proteins that assemble into viral-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLP in the vaccinated person can mimic the production of virus that occurs during natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection. Vaccines derived from MVA-VLP can elicit long-lasting immune responses in the host similar to those of a live attenuated virus, while providing the safety characteristics of a replication-defective vector.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious disease and cancer using new, proprietary platforms. The Company’s proprietary, co-owned and licensed intellectual property portfolio includes more than 70 granted or pending patent applications, spread across 20 patent families.
GeoVax’s product pipeline includes ongoing human clinical trials for COVID-19, head and neck cancer, and HIV. Other research and development programs include preventive vaccines against Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg and Lassa) and malaria, as well as immunotherapies for multiple solid tumors.
For more information about GeoVax, visit our website: www.geovax.com.
This press release contains forward-looking statements regarding GeoVax’s business plans. The words “believe”, “look forward to”, “can”, “estimate”, “continue”, “anticipate”, “intend”, “should”, “plan”, “could”, “target” “,”, “Is likely”, “will”, “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements in large part on our current expectations and projections regarding future events and financial trends that we believe could affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to various factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax immuno-oncology products and preventive vaccines can elicit the desired responses, and these products or vaccines can be used effectively, viral vector technology of GeoVax adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventive vaccines with desired characteristics in a timely manner, immuno-oncology products and preventive vaccines from GeoVax will be safe for humans, GeoVax vaccines will effectively prevent targeted infections in humans, GeoVax immuno-oncology oncology products and preventive vaccines will receive the necessary regulatory approvals to be authorized and marketed, GeoVax raises the capital required to complete the development, there is the development of Competitive products which may be more efficient or easier to use than GeoVax products, GeoVax will be able to enter into favorable manufacturing, ring and distribution agreements and other factors over which GeoVax has no control.
Further information on our risk factors is contained in our registration statement on Form S-3 and periodic reports on Forms 10-Q and 10-K that we have filed and will file with the SEC. Any forward-looking statements we make here speak only as of the date on which they are made. Factors or events that could cause our actual results to vary may occur from time to time, and we cannot predict all of them. We assume no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by US federal securities law.
GeoVax Labs, Inc.